Biomea Fusion Hold Rating: FDA Clearance and Increased Price …
WEB7 hours ago · Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with ...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes …
WEB19 hours ago · REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering ...
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
WEB1 day ago · By Connor Hart. Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug. The FDA in June put the biopharmaceutical ...
US FDA lifts clinical hold on Biomea's diabetes trials after safety ...
WEB13 hours ago · Biomea’s shares have declined 22 per cent since, but closed 9.1 per cent higher at US$9.57 (S$12.28) on Sept 26. The drug is being tested in an early-to-mid stage study for type 2 diabetes and a ...
Biomea Fusion Announces FDA Clearance of Investigational New …
WEBOct 5, 2023 · BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults with type 1 diabetes (T1D).
US FDA lifts clinical hold on Biomea's diabetes trials
WEB19 hours ago · (Reuters) -The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for type 1 and type 2 diabetes, the drug developer said on Thursday.
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 ... - Markets …
WEB9 hours ago · Biomea Fusion NewsMORE. Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up . RTTNews 8m. Biomea stock jumps 9% after FDA lifts hold on Phase 1/2 ...
Balanced Outlook with a Hold Rating for Biomea Fusion Amidst …
WEB1 day ago · The removal of the clinical hold on Biomea Fusion’s lead drug, BMF-219, used in the treatment of diabetes, has been a significant positive step, reflected by the stock’s performance.
FDA places full hold on Biomea Fusion’s diabetes trials of BMF-219
WEBJun 7, 2024 · The US Food and Drug Administration (FDA) has placed a full clinical hold on Biomea Fusion’s ongoing Phase I/II clinical trials assessing BMF-219 for type 1 and type 2 diabetes. The hold affects the COVALENT-111 and COVALENT-112 trials of BMF-219, a covalent menin inhibitor.
Biomea Fusion Highlights Recent Updates and Anticipated 2024 …
WEBJan 9, 2024 · Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.